- OUR CORPORATE FRIENDS -
Meet our friends who are doing their bit to support our #RareRevolution
|
|
|
|
|
|
|
|
|
- EVENTS -
|
Global Gene’s RARE Patient Advocacy Summit is the world’s largest gathering of rare disease patients, caregivers, thought leaders and stakeholders. This event is an unparalleled opportunity to forge meaningful connections with other rare advocates and take home actionable strategies and tools to accelerate change. Join us for the 2019 RARE Patient Advocacy Summit in San Diego, September 18-20, 2019. |
SMi Group are proud to announce the 9th Annual Orphan Drugs and Rare Diseases Conference, taking place on the 15th and 16th October 2019 in London, UK.
The orphan drug market is continuously growing and is expected to reach $176 billion by 2020, with a CGR of 10.5% just for orphan drugs – this is twice the growth rate of the overall prescription drug market (5.3% CGR from 2014-2020). By 2020, orphan drugs are set to account for 19% of global prescription sales.
This is due to the arising interest from pharmaceutical companies for underlying benefits, such as the potential discovery of mechanisms for more common diseases, and also the involvement of many smaller biotechnology start-up companies who are primarily focused on rare diseases.
The 2019 agenda features various key presentations by leading solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders discussing possible ways to accelerate orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs.
BENEFITS OF ATTENDING
PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP - Thursday 17th October 2019
A deep dive into strategies for accelerating patient access of orphan drugs
Workshop Leaders: Solange Corriol-Rohou, Senior Director Regulatory Affairs & Policy Europe, AstraZeneca
Cecile Ollivier, Chief Operating Officer, Aparito
- HEAR about the success of integrated approaches to develop a robust early access and evidence generation plan with Bionical Emas
- DISCUSS the intervention of pharmaceutical companies and patient advocates in developing lifelong rare disease treatments with Takeda
- EXPLORE the current development of strategies aimed to improve patient access to orphan drugs with Genetic Alliance UK
- GAIN INSIGHT into the various challenges facing orphan drug development with Minoryx Therapeutics
PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP - Thursday 17th October 2019
A deep dive into strategies for accelerating patient access of orphan drugs
Workshop Leaders: Solange Corriol-Rohou, Senior Director Regulatory Affairs & Policy Europe, AstraZeneca
Cecile Ollivier, Chief Operating Officer, Aparito
SMi’s 9th Annual Orphan Drugs & Rare Diseases Conference
Conference: Tuesday 15 and Wednesday 16 October 2019
Workshop: Thursday 17th October 2019
Location: Holiday Inn Kesington Forum, London, UK
Website: http://www.orphandrugs.co.uk/rarediseasemagwl
Conference: Tuesday 15 and Wednesday 16 October 2019
Workshop: Thursday 17th October 2019
Location: Holiday Inn Kesington Forum, London, UK
Website: http://www.orphandrugs.co.uk/rarediseasemagwl
Orphan Drugs
12 – 14 November, Hotel SOFIA, Barcelona
Now recognised as the largest and most established European orphan drug event, we are once again proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape. The 10th annual event will address the strategic and commercial aspects of bringing new treatments to patients who suffer from rare diseases.
For 2019 we will be expanding the meeting further with a dedicated co-conference on Cell & Gene Therapy and even more dedicated content and tracks than ever before on Clinical/Product Development, Market Access & Pricing, Manufacture, Science & Strategy, Pitch & Partner and Precision Medicine. We will also continue the highly popular Pre-Congress Workshops.
BioData World Congress
4th - 5th December, Basel
BioData World is Europe's largest big data in pharmaceutical development and healthcare congress. The congress was initially designed through a partnership with EMBL-EBI and the Sanger Institute four years ago to tackle the issues of driving big data into the clinic and pharmaceutical development in the most streamlined way possible.
The event will showcase innovation, demonstrate success and break through the obstacles and barriers to ensure that the innovations in genomics and big data enter the clinic with speed and efficiency. It will aim to make the dream of stratified medicine a reality.